Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

NCT05776524 is registered in ClinicalTrials.gov with THERABIONIC INC. as lead sponsor.

NCT NCT05776524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
Lead sponsor
THERABIONIC INC.
Phase
Phase 2
Overall status
Recruiting
Start date
June 13, 2023
Completion date
July 31, 2029
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic adenocarcinoma, pancreatic cancer